Femasys Inc(FEMY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FEMY Femasys Inc

Post-Market Trading 06-28 18:12:39 EDT

1.14

-0.01

-0.87%

盘后1.21

+0.07+6.14%

17:49 EDT

High1.16	Low1.09	Vol87.63K
Open1.14	D1 Closing1.15	Amplitude6.09%
Mkt Cap25.33M	Tradable Cap22.79M	Total Shares22.22M
T/O98.91K	T/O Rate0.44%	Tradable Shares19.99M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"FEMY","market":"US","secType":"STK","nameCN":"Femasys Inc","latestPrice":1.14,"timestamp":1719604800000,"preClose":1.15,"halted":0,"volume":87627,"hourTrading":{"tag":"盘后","latestPrice":1.21,"preClose":1.14,"latestTime":"17:49 EDT","volume":186,"amount":219.4899882,"timestamp":1719611381584},"delay":0,"floatShares":19990017,"shares":22220718,"eps":-0.83428,"marketStatus":"Post-Market Trading","change":-0.01,"latestTime":"06-28 18:12:39 EDT","open":1.14,"high":1.16,"low":1.09,"amount":98905.04179769999,"amplitude":0.06087,"askPrice":1.21,"askSize":1101,"bidPrice":0.99,"bidSize":600,"shortable":3,"etf":0,"ttmEps":-0.83428,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1719619200000},"marketStatusCode":4,"adr":0,"listingDate":1623988800000,"exchange":"NASDAQ","adjPreClose":1.15,"preHourTrading":{"tag":"盘前","latestPrice":1.16,"preClose":1.15,"latestTime":"09:28 EDT","volume":541,"amount":613.2658603,"timestamp":1719581297085},"postHourTrading":{"tag":"盘后","latestPrice":1.21,"preClose":1.14,"latestTime":"17:49 EDT","volume":186,"amount":219.4899882,"timestamp":1719611381584},"volumeRatio":0.370429},"requestUrl":"/m/hq/s/FEMY/tweets","defaultTab":"tweets","newsList":[{"id":"2446310795","title":"Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam","url":"https://stock-news.laohu8.com/highlight/detail?id=2446310795","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446310795?lang=en_us&edition=fundamental","pubTime":"2024-06-27 20:30","pubTimestamp":1719491400,"startTime":"0","endTime":"0","summary":"Leading women’s reproductive health conference directly follows the company’s EU CE Mark approval for four of its productsATLANTA, June  27, 2024  (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/06/27/2905190/0/en/Femasys-to-Participate-in-European-Society-of-Human-Reproduction-and-Embryology-40th-Annual-Meeting-in-Amsterdam.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4584","BK4082","FEMY"],"gpt_icon":0},{"id":"2445324999","title":"Gold Rises 1%; Accenture Shares Surge After Q3 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2445324999","media":"Benzinga","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2445324999?lang=en_us&edition=fundamental","pubTime":"2024-06-21 00:00","pubTimestamp":1718899255,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/06/39416585/gold-rises-1-accenture-shares-surge-after-q3-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QLD","LU0175139822.USD","BK4082","BK4091","IE00BFSS7M15.SGD","LU0949170772.SGD","TRVN","SG9999014914.USD","BK4585","MNQmain","LU0289960550.SGD","MGOL","PSQ","IE0004445015.USD","LU1032466523.USD","QQQ","SG9999014898.SGD","SGXZ31699556.SGD","BK4533","ZAPP","LU1989772840.SGD","BK4534","IE00BJJMRX11.SGD","LU0289739343.SGD","LU0323240290.USD","LU1989772923.USD","BK4588","BK4139","NQmain","BK4539","FEMY","BK4561","TPST","SQQQ",".IXIC","LU0511384066.AUD","LU0738911758.USD","SG9999018865.SGD","SONN","ACN","BK4202","SGXZ23171101.USD","IE00B7KXQ091.USD","QID","TQQQ","IE00BFSS8Q28.SGD","SG9999017495.SGD","SG9999014880.SGD","SG9999014906.USD","SG9999004303.SGD"],"gpt_icon":0},{"id":"2444246749","title":"Femasys Price Target Maintained With a $13.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2444246749","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2444246749?lang=en_us&edition=fundamental","pubTime":"2024-06-20 23:45","pubTimestamp":1718898300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FEMY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 20, 2024 11:45 ET (15:45 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FEMY"],"gpt_icon":0},{"id":"2444648246","title":"Femasys Set for Growth: Buy Rating Backed by EU Regulatory Success and Strategic U.S. Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2444648246","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2444648246?lang=en_us&edition=fundamental","pubTime":"2024-06-20 23:25","pubTimestamp":1718897122,"startTime":"0","endTime":"0","summary":"Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Femasys (FEMY – Research Report). The associated price target remains t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/femasys-set-for-growth-buy-rating-backed-by-eu-regulatory-success-and-strategic-u-s-expansion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/femasys-set-for-growth-buy-rating-backed-by-eu-regulatory-success-and-strategic-u-s-expansion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FEMY"],"gpt_icon":0},{"id":"2444521267","title":"Femasys Secures CE Mark Approvals for Four Women's Health Products; Shares Up Over 14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2444521267","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2444521267?lang=en_us&edition=fundamental","pubTime":"2024-06-20 21:45","pubTimestamp":1718891156,"startTime":"0","endTime":"0","summary":"Femasys  said Thursday it received CE Mark certifications for four of its women's health products, certifying that the products comply with new European Union regulations for medical devices. The company said the CE Mark approvals come on the heels of the products' European Union Medical Device Regulation certificates and will pave the way for the start of product commercialization in Europe.Shares of Femasys were up more than 14% in recent early Thursday trading.Price: 1.09, Change: +0.14, Percent Change: +14.14","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4082","BK4585","CE","BK4109","FEMY","BK4584","BK4588"],"gpt_icon":0},{"id":"2444154802","title":"Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2444154802","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2444154802?lang=en_us&edition=fundamental","pubTime":"2024-06-20 20:30","pubTimestamp":1718886600,"startTime":"0","endTime":"0","summary":"ATLANTA, June  20, 2024  (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-o","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/06/20/2901685/0/en/Femasys-Receives-CE-Mark-Approval-for-Four-of-its-Women-s-Health-Products-Clearing-the-Path-for-the-Company-to-Begin-Commercialization-Efforts-in-Europe.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4585","BK4584","BK4539","FEMY","CE","BK4109","BK4588"],"gpt_icon":0},{"id":"2436828916","title":"Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative","url":"https://stock-news.laohu8.com/highlight/detail?id=2436828916","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2436828916?lang=en_us&edition=fundamental","pubTime":"2024-05-17 12:30","pubTimestamp":1715920200,"startTime":"0","endTime":"0","summary":"Lee-Sepsick Discussed Company’s FemCerv Endocervical Tissue Sampler and its Role in Cervical Cancer DiagnosisATLANTA, May  17, 2024  (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/17/2884217/0/en/Femasys-CEO-and-Founder-Kathy-Lee-Sepsick-Meets-with-the-White-House-s-Office-of-Science-and-Technology-Policy-to-Discuss-the-Cancer-Moonshot-Initiative.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FEMY"],"gpt_icon":0},{"id":"2435674043","title":"Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council","url":"https://stock-news.laohu8.com/highlight/detail?id=2435674043","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435674043?lang=en_us&edition=fundamental","pubTime":"2024-05-16 20:30","pubTimestamp":1715862600,"startTime":"0","endTime":"0","summary":"Lee-Sepsick Discussed Atlanta-Based Biomedical Company’s Women’s Reproductive Health Products. Femasys is an Atlanta-based company that provides minimally invasive women’s reproductive health solutions, which are manufactured in the U.S. Later this week, the Company will be displaying its four commercially available products: FemaSeed – FDA-cleared, intratubal insemination; FemVue – contrast-generating device; FemCath – selective delivery catheter; FemCerv – endocervical tissue sampler; and its current lead product candidate in late-stage clinical development FemBloc – a non-surgical, non-hormonal permanent birth control, at the 2024 American College of Obstetricians and Gynecologists  Annua","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/K4bE7sAlvu9T6IFX8NJ7bA--~B/aD0xNzU7dz00MzI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/bd12f0f0012b2cb2c1b7eb600db063f9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/K4bE7sAlvu9T6IFX8NJ7bA--~B/aD0xNzU7dz00MzI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/bd12f0f0012b2cb2c1b7eb600db063f9"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/femasys-ceo-founder-kathy-lee-123000762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FEMY"],"gpt_icon":0},{"id":"2434875093","title":"Femasys’s Buy Rating Affirmed by Analyst Jason McCarthy on FemaSeed’s Market Success and Robust Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2434875093","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434875093?lang=en_us&edition=fundamental","pubTime":"2024-05-11 23:45","pubTimestamp":1715442317,"startTime":"0","endTime":"0","summary":"Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Femasys (FEMY – Research Report). The associated price target remains the...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/femasyss-buy-rating-affirmed-by-analyst-jason-mccarthy-on-femaseeds-market-success-and-robust-clinical-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/femasyss-buy-rating-affirmed-by-analyst-jason-mccarthy-on-femaseeds-market-success-and-robust-clinical-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4082","FEMY","BK4584"],"gpt_icon":0},{"id":"2434010669","title":"Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK) and Femasys (FEMY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2434010669","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434010669?lang=en_us&edition=fundamental","pubTime":"2024-05-10 00:40","pubTimestamp":1715272807,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Hookipa Pharma (HOOK – Research Report) and Femasys ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-hookipa-pharma-hook-and-femasys-femy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-hookipa-pharma-hook-and-femasys-femy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4539","HOOK","BK4584","BK4082","BK4139","HCSG","BK4505","FEMY"],"gpt_icon":0},{"id":"2434011975","title":"Femasys GAAP EPS of -$0.17, revenue of $0.27M","url":"https://stock-news.laohu8.com/highlight/detail?id=2434011975","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434011975?lang=en_us&edition=fundamental","pubTime":"2024-05-09 23:07","pubTimestamp":1715267222,"startTime":"0","endTime":"0","summary":"Femasys press release  (NASDAQ:FEMY): Q1  GAAP EPS of -$0.17.\nRevenue of $0.27M (-6.9% Y/Y).\nCash and cash equivalents as of March 31, 2024, was $17.8M.\nExpects its existing cash and cash equivalents will be sufficient to fund its ongoing operations into the second half of 2025.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4103804-femasys-gaap-eps-of-0_17-revenue-of-0_27m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["FEMY"],"gpt_icon":0},{"id":"2434010523","title":"Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2434010523","media":"Zacks","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434010523?lang=en_us&edition=fundamental","pubTime":"2024-05-09 21:40","pubTimestamp":1715262002,"startTime":"0","endTime":"0","summary":"Femasys Inc.  came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.25 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 22.73%. A quarter ago, it was expected that this company would post a loss of $0.19 per share when it actually produced a loss of $0.19, delivering no surprise.Over the last four quarters, the company has surpassed consensus EPS estimates just once.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% o","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/9naTdeJlVMX28sdlDpLdrQ--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ac90b3d74679f6d01a122aa033d8a9a4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/9naTdeJlVMX28sdlDpLdrQ--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ac90b3d74679f6d01a122aa033d8a9a4"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/femasys-inc-femy-reports-q1-134002528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FEMY"],"gpt_icon":0},{"id":"2434922610","title":"Femasys Q1 2024 GAAP EPS $(0.17) Beats $(0.19) Estimate, Sales $271.140K Miss $776.500K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2434922610","media":"Benzinga","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434922610?lang=en_us&edition=fundamental","pubTime":"2024-05-09 20:41","pubTimestamp":1715258468,"startTime":"0","endTime":"0","summary":"Femasys (NASDAQ:FEMY) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.19) by 10.53 percent.  The company reported quarterly sales of $271.140 thousand which missed the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38730439/femasys-q1-2024-gaap-eps-0-17-beats-0-19-estimate-sales-271-140k-miss-776-500k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FEMY"],"gpt_icon":0},{"id":"2434094614","title":"Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2434094614","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434094614?lang=en_us&edition=fundamental","pubTime":"2024-05-09 12:30","pubTimestamp":1715229000,"startTime":"0","endTime":"0","summary":"-- Recruitment of the commercial team for our infertility portfolio and the pivotal trial of FemBloc for permanent non-surgical birth control continues -- ATLANTA, May  09, 2024  (GLOBE NEWSWIRE) -- F","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/09/2878750/0/en/Femasys-Announces-Financial-Results-for-Quarter-Ended-March-31-2024-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","FEMY","BK4584","BK4539"],"gpt_icon":0},{"id":"2433206525","title":"Femasys Expands Commercial Management Team with Addition of Experienced New Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2433206525","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2433206525?lang=en_us&edition=fundamental","pubTime":"2024-05-07 12:30","pubTimestamp":1715056200,"startTime":"0","endTime":"0","summary":"Team to Drive Strategic Initiatives, Launching Efforts at 2024 ACOG MeetingATLANTA, May  07, 2024  (GLOBE NEWSWIRE) -- Femasys Inc. (Nasdaq: FEMY), a leading biomedical company focused on addressing s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/07/2876741/0/en/Femasys-Expands-Commercial-Management-Team-with-Addition-of-Experienced-New-Hires.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FEMY","BK4584","BK4082","TISI","BK4120","BK4539"],"gpt_icon":0},{"id":"2429459051","title":"Femasys Releases Updated Investor Presentation Information","url":"https://stock-news.laohu8.com/highlight/detail?id=2429459051","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2429459051?lang=en_us&edition=fundamental","pubTime":"2024-04-24 21:22","pubTimestamp":1713964936,"startTime":"0","endTime":"0","summary":"The latest update is out from Femasys (FEMY). Femasys Inc. has recently updated its investor presentation and made it available on its website. Thi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/femasys-releases-updated-investor-presentation-information?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/femasys-releases-updated-investor-presentation-information?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FEMY","BK4584","BK4082","BK4134","III","BK4539"],"gpt_icon":0},{"id":"2428593548","title":"Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2428593548","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2428593548?lang=en_us&edition=fundamental","pubTime":"2024-04-18 12:30","pubTimestamp":1713414600,"startTime":"0","endTime":"0","summary":"ATLANTA, April  18, 2024  (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-of","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/18/2865390/0/en/Femasys-CEO-and-Founder-Kathy-Lee-Sepsick-Meets-with-Members-of-Congress-to-Raise-Awareness-of-the-Company-and-Discuss-Women-s-Healthcare-Initiatives.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FEMY","HCSG"],"gpt_icon":0},{"id":"2424883072","title":"Femasys: A Buy Rating on Innovative Reproductive Solutions and Market Expansion Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2424883072","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2424883072?lang=en_us&edition=fundamental","pubTime":"2024-04-03 03:45","pubTimestamp":1712087123,"startTime":"0","endTime":"0","summary":"Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Femasys (FEMY – Research Report). The associated price target remains the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/femasys-a-buy-rating-on-innovative-reproductive-solutions-and-market-expansion-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/femasys-a-buy-rating-on-innovative-reproductive-solutions-and-market-expansion-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","FEMY","BK4082","BK4584"],"gpt_icon":0},{"id":"2423863222","title":"Femasys Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag","url":"https://stock-news.laohu8.com/highlight/detail?id=2423863222","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2423863222?lang=en_us&edition=fundamental","pubTime":"2024-03-31 21:06","pubTimestamp":1711890416,"startTime":"0","endTime":"0","summary":"NasdaqCM:FEMY Earnings and Revenue Growth March 31st 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 8.9%. Earnings per share  exceeded analyst estimates by 1.8%.Looking ahead, revenue is forecast to grow 55% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US.The company's shares are down 6.6% from a week ago.Don't forget that there may still be risks. For instance, we've identified   5 warning signs for Femasys   you should be aware of.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/femasys-full-2023-earnings-eps-130656898.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FEMY"],"gpt_icon":0},{"id":"2423107014","title":"Femasys Q4 EPS $(0.19) Beats $(0.21) Estimate, Sales $213.11K Miss $240.00K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2423107014","media":"Benzinga","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2423107014?lang=en_us&edition=fundamental","pubTime":"2024-03-29 11:38","pubTimestamp":1711683535,"startTime":"0","endTime":"0","summary":"Femasys (NASDAQ:FEMY) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 20.83 percent increase over losses of $(0.24) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/03/38000272/femasys-q4-eps-0-19-beats-0-21-estimate-sales-213-11k-miss-240-00k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FEMY"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.femasys.com","stockEarnings":[{"period":"1week","weight":-0.0945},{"period":"1month","weight":-0.0496},{"period":"3month","weight":-0.2581},{"period":"6month","weight":0.1795},{"period":"1year","weight":1.0811},{"period":"ytd","weight":0.1795}],"compareEarnings":[{"period":"1week","weight":-0.0012},{"period":"1month","weight":0.0313},{"period":"3month","weight":0.0445},{"period":"6month","weight":0.1495},{"period":"1year","weight":0.252},{"period":"ytd","weight":0.1495}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. In addition, the company provides non-surgical product technologies. It offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.040211},{"month":2,"riseRate":0.333333,"avgChangeRate":0.417878},{"month":3,"riseRate":0,"avgChangeRate":-0.124004},{"month":4,"riseRate":0,"avgChangeRate":-0.217713},{"month":5,"riseRate":0,"avgChangeRate":-0.109081},{"month":6,"riseRate":0.333333,"avgChangeRate":0.089361},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.105285},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.035972},{"month":9,"riseRate":0.333333,"avgChangeRate":1.762551},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.127502},{"month":11,"riseRate":0,"avgChangeRate":-0.241048},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.139272}],"exchange":"NASDAQ","name":"Femasys Inc","nameEN":"Femasys Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Femasys Inc(FEMY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Femasys Inc(FEMY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Femasys Inc,FEMY,Femasys Inc股票,Femasys Inc股票老虎,Femasys Inc股票老虎国际,Femasys Inc行情,Femasys Inc股票行情,Femasys Inc股价,Femasys Inc股市,Femasys Inc股票价格,Femasys Inc股票交易,Femasys Inc股票购买,Femasys Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Femasys Inc(FEMY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Femasys Inc(FEMY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction